This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET)


Drye, Lea T., Scherer, Roberta W., Lanctôt, Krista L., Rosenberg, Paul B., Herrmann, Nathan, Bachman, David, Mintzer, Jacobo E.


The American Journal Of Geriatric Psychiatry: Official Journal Of The American Association For Geriatric Psychiatry, Volume: 21, No.: 6, Pages.: 549-559

Year of Publication



Background: Research on efficacious treatments for apathy in Alzheimer disease has been hindered by a lack of consensus diagnosis, difficulties in measurement, and studies with small sample sizes.; Methods: In designing the Apathy in Dementia Methylphenidate Trial (ADMET), a trial to evaluate the efficacy and safety of methylphenidate for the treatment of apathy in Alzheimer disease, we encountered the following issues: defining and measuring apathy, distinguishing apathy and depression, determining an appropriate test treatment, selecting relevant secondary outcomes, recruiting participants, and deciding on a suitable method for treatment unmasking. ADMET is a 6-week randomized, double-masked, placebo-controlled multicenter clinical trial with two parallel treatment groups assigned in a 1:1 ratio with randomization stratified by clinical center. The recruitment goal is 60 randomized participants over 2 years. The primary outcomes are change in apathy severity as measured by the Apathy Evaluation Scale and the Alzheimer Disease Cooperative Study-Clinical Global Impression of Change.; Conclusion: The design decisions made for ADMET are important elements to be considered in trials assessing the safety and efficacy of medications for clinically significant apathy in Alzheimer disease.; Copyright © 2013 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.

Bibtex Citation

@article{Drye_2013, doi = {10.1016/j.jagp.2012.12.018}, url = {}, year = 2013, month = {jun}, publisher = {Elsevier {BV}}, volume = {21}, number = {6}, pages = {549--559}, author = {Lea T. Drye and Roberta W. Scherer and Krista L. Lanct{^{o}}t and Paul B. Rosenberg and Nathan Herrmann and David Bachman and Jacobo E. Mintzer}, title = {Designing a Trial to Evaluate Potential Treatments for Apathy in Dementia: The Apathy in Dementia Methylphenidate Trial ({ADMET})}, journal = {The American Journal of Geriatric Psychiatry} }


apathy, dementia, double-blind method, drug effects, drug therapy, humans, methods, methylphenidate, psychology, randomized controlled trials as topic, research design, therapeutic use

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions